OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001)100% ...

OS Therapies’ cancer vaccine, OST-HER2, has been shown to significantly improve overall survival (OS) in patients with recurrent, fully resected, pulmonary metastatic osteosarcoma after two years.

Extracorporeal irradiation and reimplantation for bone sarcomas: Medium- and long-term oncologic and functional outcomes. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...

Researchers at Cleveland Clinic Children's have helped identify a previously unknown gene that increases the risk of ...

UCLA scientists, together with a team of international collaborators, have identified a promising new treatment strategy that ...

Purpose: The prognosis for patients who develop metachronous skeletal osteosarcoma (OS) has been considered grave compared with that for patients with relapse limited to the lungs. We investigated the ...

Osteosarcoma is a malignant neoplasm of the bone and is the most common histological form of primary bone cancer. It is most prevalent in children and young adults, as it is associated with the ...

Currently, the standard approach for treatment of patients with osteosarcoma consists of 10 weeks of preoperative chemotherapy, surgical resection and 20 weeks of postoperative chemotherapy. While ...

Yet to be published data from clinical study combining OST-HER2 with palliative radiation in dogs with unresected, primary osteosarcoma shows clinical and radiographic arrest of the primary tumor, ...